Immunogenicity of Biopharmaceuticals (inbunden)
Format
Inbunden (Hardback)
Språk
Engelska
Antal sidor
266
Utgivningsdatum
2008-03-01
Upplaga
2008 ed.
Förlag
Springer-Verlag New York Inc.
Medarbetare
Van de Weert, Marco (ed.), Møller, Eva Horn (ed.)
Illustratör/Fotograf
18 schw-w Tabellen 27 schw-w und 2 farb Abb
Illustrationer
18 Tables, black and white; XII, 266 p.
Dimensioner
262 x 179 x 21 mm
Vikt
745 g
Antal komponenter
1
Komponenter
1 Hardback
ISBN
9780387758404
Immunogenicity of Biopharmaceuticals (inbunden)

Immunogenicity of Biopharmaceuticals

Inbunden Engelska, 2008-03-01
2239
Skickas inom 10-15 vardagar.
Fri frakt inom Sverige för privatpersoner.
Finns även som
Visa alla 2 format & utgåvor
Immunogenicity of Biopharmaceuticals is the first book to comprehensively address the potential of an immune response to biopharmaceuticals. It is intended to give a broad overview of the current state-of-the-art regarding this subject. The chapters range from an overview of the immune system and factors that may trigger the immune system, via detection of antibodies and clinical implications, to various case examples and the regulatory view on immunogenicity.
Visa hela texten

Passar bra ihop

  1. Immunogenicity of Biopharmaceuticals
  2. +
  3. Tracing Mobilities

De som köpt den här boken har ofta också köpt Tracing Mobilities av Weert Canzler, Vincent Kaufmann (inbunden).

Köp båda 2 för 3738 kr

Kundrecensioner

Har du läst boken? Sätt ditt betyg »

Innehållsförteckning

Immune Reactions Towards Biopharmaceuticals - a General, Mechanistic Overview.- Clinical Aspects of Immunogenicity to Biopharmaceuticals.- Assessment of Unwanted Immunogenicity.- Models for Prediction of Immunogenicity.- Immunogenicity of Biopharmaceuticals: Causes, Methods to Reduce Immunogenicity, and Biosimilars.- Case Study: Immunogenicity of rhEPO.- Case Study: Immunogenicity of Interferon-Beta.- Case Study: Immunogenicity of Insulin.- Case Study: Immunogenicity of Factor VIII.- Case Study: Immunogenicity of Natalizumab.- Case Study: Immunogenicity of Anti-TNF Antibodies.- Heparin-Induced Thrombocytopenia.- Presenting an Immunogenicity Risk Assessment to Regulatory Agencies.